title: Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
abstract: Centrally acting antihypertensive drugs are recognized to be safe and effective treatment for high blood pressure. Centrally mediated side effects, such as sedation, are commonly dose- and treatment-limiting events. Imidazoline-preferring receptors, while functionally similar to alpha 2 adrenoceptors, are distinguishable not only on the basis of in vitro radioligand binding but also in vivo in terms of side effects. Drugs with an imidazoline structure lower blood pressure but are less likely to impair psychomotor function. A placebo-controlled study compared moxonidine 0.1 mg with clonidine 0.1 mg orally in nine normal subjects. Both active drugs lowered blood pressure compared to placebo (clonidine more than moxonidine). However, psychomotor function and self-scored sedation and dry mouth were significantly affected only by clonidine. In a long-term (4 weeks) double-blind cross-over study in essential hypertension, rilmenidine was well tolerated and had similar effects to those of atenolol on erect and supine blood pressure. Rilmenidine had no effect on a wide range of autonomic and psychomotor tests or on responses to mental or physical stress. Atenolol, by contrast, had the predicted effects of a beta adrenoceptor antagonist on heart rate during exercise and the Valsalva maneuver. Imidazoline-preferring drugs offer a new and realistic approach to antihypertensive therapy with blood pressure reduction not limited by marked sedation within the therapeutic dose range.
authors.affiliation: Department of Medicine and Therapeutics, University of Glasgow, Scotland.
authors.forename: J L
authors.initials: JL
authors.lastname: Reid
authors.forename: V
authors.initials: V
authors.lastname: Panfilov
authors.forename: G
authors.initials: G
authors.lastname: MacPhee
authors.forename: H L
authors.initials: HL
authors.lastname: Elliott
mesh_terms: D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001262:Atenolol / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D054755:Imidazoline Receptors; D010080:Oxazoles / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011955:Receptors, Drug / Q000187:drug effects*; D012016:Reference Values; D000077769:Rilmenidine
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; D010080:Oxazoles; D010919:Placebos; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D001262:Atenolol; C043482:moxonidine; D003000:Clonidine; D000077769:Rilmenidine